Back to Search Start Over

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -- United States, December 2020.

Authors :
Oliver, Sara E.
Gargano, Julia W.
Marin, Mona
Wallace, Megan
Curran, Kathryn G.
Chamberland, Mary
McClung, Nancy
Campos-Outcalt, Doug
Morgan, Rebecca L.
Mbaeyi, Sarah
Romero, José R.
Talbot, H. Keipp
Lee, Grace M.
Bell, Beth P.
Dooling, Kathleen
Source :
MMWR: Morbidity & Mortality Weekly Report. 12/18/2020, Vol. 69 Issue 50, p1922-1924. 3p.
Publication Year :
2020

Abstract

What is already known about this topic? On December 11, 2020, the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine. What is added by this report? On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for the prevention of COVID-19. What are the implications for public health practice? The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01492195
Volume :
69
Issue :
50
Database :
Academic Search Index
Journal :
MMWR: Morbidity & Mortality Weekly Report
Publication Type :
Academic Journal
Accession number :
147695830
Full Text :
https://doi.org/10.15585/mmwr.mm6950e2